Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
View Patent ↗Nucleic acids encoding mouse and human sphingosine kinase type 2 isoforms, methods for detecting agents or drugs which inhibit or promote sphingosine activity and therapeutic agents containing peptides or antibodies to peptides encoded by such nucleic acids.
1. An isolated protein selected from the group consisting of (a) a protein having an amino acid sequence consisting essentially of SEQ ID NO: 14 and (b) a protein encoded by a nucleotide sequence consisting essentially of SEQ ID NO: 13.
2. A method of regulating a biological process selected from the group consisting of mitogenesis, apoptosis, neuronal development, chemotaxis, angiogenesis and an inflammatory response in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of the protein according to claim 1 .
3. The method of claim 2 , wherein the mammal is a human.
4. The method of claim 3 , wherein the biological process is angiogenesis.
5. A method for the treatment or amelioration of a disease resulting from increased cell death or decreased cell proliferation, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a protein according to claim 1 .
6. The method of claim 5 , wherein the mammal is a human.
7. A composition for treating or ameliorating a disease resulting from increased cell death or decreased cell proliferation comprising a pharmaceutically effective amount of a protein according to claim 1 , and a pharmaceutically acceptable carrier.
8. A method for the treatment or amelioration of developmental retardation in a human comprising administering to a human in need thereof a pharmaceutically effective amount of the protein according to claim 1 .
9. A method for detecting an agent or a drug which inhibits or promotes an enzymatic activity of human sphingosine kinase type 2 isoform comprising:
(i) contacting a human sphingosine kinase type 2isoform protein according to claim 1 and lipids in the presence of at least one drug or agent;
(ii) detecting whether or not said drug or agent inhibits or promotes the enzymatic activity of the sphingosine kinase type 2 isoform by measuring sphingosine kinase type 2-dependent phosphorylation of the lipids and comparing the resultant measurement to a control which did not receive the drug or agent, wherein a decrease in the amount of sphingosine kinase type 2-dependent phosphorylation of the lipids as compared to the control indicates an inhibitory drug or agent, or an increase in the amount of sphingosine kinase type 2-dependent phosphorylation of the lipids as compared to the control indicates a stimulatory drug or agent.
10. A method for the treatment or amelioration of a disease resulting from decreased cell death or increased cell proliferation comprising administering to a mammal in need thereof a pharmaceutically effective amount of an antibody to a protein according to claim 1 .
11. The method of claim 10 , wherein the mammal is a human.
12. A method for the treatment or amelioration of a disease resulting from abnormal migration or motility of cells selected from the group consisting of cancer, restenosis and diabetic neuropathy, the method comprising administering to a mammal in need thereof, a pharmaceutically effective amount of an antibody to a protein according to claim 1 .
13. The method of claim 12 , wherein the mammal is a human.
14. The method according to claim 9 , wherein in step (i), said human sphingosine kinase type 2 isoform protein is produced by a host cell having a recombinant vector comprising a polynucleotide having the nucleotide sequence of SEQ ID NO:13.
15. The method according to claim 9 , wherein said lipids comprise at least one of D, L-threo-dihydrosphingosine and phytosphingosine.